KYMR Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Kymera Therapeutics Inc (KYMR) is not a strong buy for a beginner, long-term investor at this moment. While the company has promising technology and potential future catalysts, the stock is currently overbought based on technical indicators, and there are no immediate strong trading signals or significant positive catalysts to justify an entry point. A hold position is more appropriate until better entry points or further developments arise.
The stock is in a bullish trend with MACD positively expanding and moving averages aligned bullishly (SMA_5 > SMA_20 > SMA_200). However, the RSI is at 83.622, indicating an overbought condition. Key resistance levels are at 90.13 and 94.779, with support at 75.079 and 70.43.
Analysts project significant revenue potential for KT-621 in the long term.
The RSI indicates the stock is overbought, suggesting a potential pullback. Additionally, key clinical readouts for KT-621 are still several years away, limiting near-term catalysts.
No financial data is available for analysis.
Analysts are generally positive on the stock, with Canaccord initiating a Buy rating and a $106 price target, and Morgan Stanley maintaining an Overweight rating with a slightly reduced price target of $119. However, these targets are based on long-term projections.
